Powder: -20°C for 3 years | In solvent: -80°C for 1 year
VEGFR-3-IN-1 是一种新型有效且具有选择性的 VEGFR3 抑制剂,其 IC50 为 110.4 nM。VEGFR-3-IN-1 具有抗肿瘤活性,可使 VEGFR3 信号通路失活,可抑制 VEGF-C 诱导人真皮淋巴管内皮细胞 (HDLEC)、MDA-MB-231 和 MDA-MB-436 细胞的增殖和迁移,并且能有效抑制乳腺癌的生长。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 478 | 现货 | ||
5 mg | ¥ 1,160 | 现货 | ||
10 mg | ¥ 1,890 | 现货 | ||
25 mg | ¥ 3,820 | 现货 | ||
50 mg | ¥ 6,230 | 现货 | ||
100 mg | ¥ 8,390 | 现货 | ||
500 mg | ¥ 16,800 | 现货 |
产品描述 | VEGFR-3-IN-1 is a novel potent and selective VEGFR3 inhibitor with an IC50 of 110.4 nM.VEGFR-3-IN-1 possesses antitumor activity, inactivates the VEGFR3 signaling pathway, and inhibits the proliferation and migration of VEGF-C-induced human dermal lymphatic endothelial cells (HDLEC), MDA-MB-231 and MDA-MB-436 cells. MB-436 cells and inhibited the proliferation and migration of human dermal lymphatic endothelial cells (HDLEC), MDA-MB-231 and MDA-MB-436 cells. |
靶点活性 | VEGFR3:110.4 nM |
体外活性 |
VEGFR-3-IN-1 (compound 38k) (100 nM; 48 hours) demonstrates significantly enhanced antiproliferative efficacy against MDA-MB-231 and MDA-MB-436 cells with IC50 values of 2.22 and 3.50 μM, respectively.[1] VEGFR-3-IN-1 markedly suppresses the phosphorylation of VEGFR3 and its downstream proteins in a dose-dependent manner.[1] |
体内活性 |
VEGFR-3-IN-1 (50, 25 mg/kg; p.o.; once; Nude mice), with a growth inhibition rate of 61.9%, achieves the most potent inhibition of tumor volume in mice.[1] VEGFR-3-IN-1 (10 mg/kg; p.o.) treatment results in the following values: Cmax of 420 ng/mL, AUC0-t of 9219 ng h/mL, AUC0-∞ of 12304 ng h/mL, and t1/2 of 16 hours.[1] |
分子量 | 616.1 |
分子式 | C29H29ClF3N7OS |
CAS No. | 2756668-73-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 5 mg/mL (8.12 mM), when pH is adjusted to 6 with HCl. Sonication and heating are recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.6231 mL | 8.1156 mL | 16.2311 mL | 40.5778 mL |
5 mM | 0.3246 mL | 1.6231 mL | 3.2462 mL | 8.1156 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
VEGFR-3-IN-1 2756668-73-0 Angiogenesis Tyrosine Kinase/Adaptors VEGFR Inhibitor inhibitor inhibit